Literature DB >> 20719219

Human papillomavirus vaccine acceptability among a national sample of adult women in the USA.

Nathan W Stupiansky1, Susan L Rosenthal, Sarah E Wiehe, Gregory D Zimet.   

Abstract

BACKGROUND: In the USA, the human papillomavirus (HPV) vaccine is currently licensed for 9-26-year-old females, but licensure for women over 26 years is being considered. The aim of the current study was to investigate the association of sociodemographic and health-related factors to HPV vaccine acceptability among adult women.
METHODS: The current study utilised a nationally representative sample of women (n = 1323) aged 27-55 living in the USA, with an oversampling of black and Latina women. A multiple item measure of HPV vaccine acceptability across varying cost and location-of-availability (clinic only v. any local pharmacy) conditions was the main outcome measure. General linear modelling was used to analyse the association of vaccine cost, location availability, and sociodemographic and health-related variables with vaccine acceptability.
RESULTS: Vaccine cost had the strongest association with acceptability [F (2, 1249) = 832.1; P < 0.0001]; however, factors such as religiosity, political views, a history of various negative sexual health outcomes and previous flu shot receipt were also associated with acceptability. Location availability had a statistically significant but modest effect, with a slight preference shown for health clinic availability.
CONCLUSIONS: Adult women had generally high levels of HPV vaccine acceptability, but were greatly influenced by cost of the vaccine. Women who had experienced negative sexual health outcomes due to HPV-specific infection rated the vaccine as more acceptable, perhaps due to distress associated with those outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719219     DOI: 10.1071/SH09127

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  7 in total

1.  Effects of a narrative HPV vaccination intervention aimed at reaching college women: a randomized controlled trial.

Authors:  Suellen Hopfer
Journal:  Prev Sci       Date:  2012-04

2.  Quadrivalent human papillomavirus vaccine uptake in adolescent boys and maternal utilization of preventive care and history of sexually transmitted infections.

Authors:  Rulin C Hechter; Chun Chao; Lina S Sy; Bradley K Ackerson; Jeff M Slezak; Margo A Sidell; Steven J Jacobsen
Journal:  Am J Public Health       Date:  2013-07-18       Impact factor: 9.308

3.  Factors associated with HPV vaccination among adult women in Quebec.

Authors:  Marilou Kiely; Chantal Sauvageau; Eve Dubé; Genevieve Deceuninck; Philippe De Wals
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

4.  Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City.

Authors:  Betania Allen-Leigh; Leonor Rivera-Rivera; Elsa Yunes-Díaz; Alejandra Jalil Portillo-Romero; Brandon Brown; Leith León-Maldonado; Galileo Vargas-Guadarrama; Jorge Salmerón; Eduardo Cesar Lazcano-Ponce
Journal:  Hum Vaccin Immunother       Date:  2019-11-01       Impact factor: 3.452

Review 5.  Antibody-based concepts for multipurpose prevention technologies.

Authors:  Kevin J Whaley; Larry Zeitlin
Journal:  Antiviral Res       Date:  2013-11-01       Impact factor: 5.970

6.  Attitudes toward HPV Vaccination among Women Aged 27 to 45.

Authors:  Thomas W Weiss; Susan L Rosenthal; Gregory D Zimet
Journal:  ISRN Obstet Gynecol       Date:  2011-04-07

7.  Vaccinating sons against HPV: results from a U.S. national survey of parents.

Authors:  Jaime L Taylor; Greg D Zimet; Kelly L Donahue; Andreia B Alexander; Marcia L Shew; Nathan W Stupiansky
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.